Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis
Serum α-fetoprotein- (AFP-) elevated gastric cancer is a rare tumor that has a poor prognosis due to high incidence of liver metastasis. This study sought to investigate the optimal treatment modality. A total of 319 gastric cancer patients with liver metastasis (GCLM) whose serum AFP levels were te...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/5080361 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832563117380337664 |
|---|---|
| author | Yakun Wang Lin Shen Ming Lu Zhi Ji Xiaotian Zhang |
| author_facet | Yakun Wang Lin Shen Ming Lu Zhi Ji Xiaotian Zhang |
| author_sort | Yakun Wang |
| collection | DOAJ |
| description | Serum α-fetoprotein- (AFP-) elevated gastric cancer is a rare tumor that has a poor prognosis due to high incidence of liver metastasis. This study sought to investigate the optimal treatment modality. A total of 319 gastric cancer patients with liver metastasis (GCLM) whose serum AFP levels were tested before treatment were enrolled in this study. They were classified as the serum AFP ≥ 20 ng/ml group (n=74) and the AFP < 20 ng/ml group (n=245). Median OS of the AFP < 20 ng/ml group was significantly longer than that of the AFP ≥ 20 ng/ml group (15.7 m versus 10.9 m, P=0.004). ORR of first-line chemotherapy was 43.3% and 56.1% of the two groups, respectively (P=0.024). Of patients who received doublet regimen, ORR of the AFP ≥ 20 ng/ml group was significantly lower (38.2 versus 56.9%, P=0.013), while in those received triplet regimens, ORR between two groups was similar (66.7% versus 66.7%, P=0.676). Moreover, for patients of the AFP ≥ 20 ng/ml group, those who reached PR had a longer survival period (15.4 m versus 9.4 m, P=0.017), and combined with local treatment for liver metastasis also seemed to improve prognosis (19.2 m versus 8.4 m, P=0.003). In conclusion, serum AFP-elevated GCLM had a poorer prognosis. Multimodality treatment including aggressive first-line chemotherapy with triplet regimen may be needed when treating them. |
| format | Article |
| id | doaj-art-d2c69cf123294614b7cec8ee447cefb7 |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-d2c69cf123294614b7cec8ee447cefb72025-02-03T01:20:57ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/50803615080361Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver MetastasisYakun Wang0Lin Shen1Ming Lu2Zhi Ji3Xiaotian Zhang4Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing 100142, ChinaDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, No. 52, Fucheng Road, Haidian District, Beijing 100142, ChinaSerum α-fetoprotein- (AFP-) elevated gastric cancer is a rare tumor that has a poor prognosis due to high incidence of liver metastasis. This study sought to investigate the optimal treatment modality. A total of 319 gastric cancer patients with liver metastasis (GCLM) whose serum AFP levels were tested before treatment were enrolled in this study. They were classified as the serum AFP ≥ 20 ng/ml group (n=74) and the AFP < 20 ng/ml group (n=245). Median OS of the AFP < 20 ng/ml group was significantly longer than that of the AFP ≥ 20 ng/ml group (15.7 m versus 10.9 m, P=0.004). ORR of first-line chemotherapy was 43.3% and 56.1% of the two groups, respectively (P=0.024). Of patients who received doublet regimen, ORR of the AFP ≥ 20 ng/ml group was significantly lower (38.2 versus 56.9%, P=0.013), while in those received triplet regimens, ORR between two groups was similar (66.7% versus 66.7%, P=0.676). Moreover, for patients of the AFP ≥ 20 ng/ml group, those who reached PR had a longer survival period (15.4 m versus 9.4 m, P=0.017), and combined with local treatment for liver metastasis also seemed to improve prognosis (19.2 m versus 8.4 m, P=0.003). In conclusion, serum AFP-elevated GCLM had a poorer prognosis. Multimodality treatment including aggressive first-line chemotherapy with triplet regimen may be needed when treating them.http://dx.doi.org/10.1155/2017/5080361 |
| spellingShingle | Yakun Wang Lin Shen Ming Lu Zhi Ji Xiaotian Zhang Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis Gastroenterology Research and Practice |
| title | Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis |
| title_full | Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis |
| title_fullStr | Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis |
| title_full_unstemmed | Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis |
| title_short | Multimodality Treatment Including Triplet Regimen as First-Line Chemotherapy May Improve Prognosis of Serum AFP-Elevated Gastric Cancer with Liver Metastasis |
| title_sort | multimodality treatment including triplet regimen as first line chemotherapy may improve prognosis of serum afp elevated gastric cancer with liver metastasis |
| url | http://dx.doi.org/10.1155/2017/5080361 |
| work_keys_str_mv | AT yakunwang multimodalitytreatmentincludingtripletregimenasfirstlinechemotherapymayimproveprognosisofserumafpelevatedgastriccancerwithlivermetastasis AT linshen multimodalitytreatmentincludingtripletregimenasfirstlinechemotherapymayimproveprognosisofserumafpelevatedgastriccancerwithlivermetastasis AT minglu multimodalitytreatmentincludingtripletregimenasfirstlinechemotherapymayimproveprognosisofserumafpelevatedgastriccancerwithlivermetastasis AT zhiji multimodalitytreatmentincludingtripletregimenasfirstlinechemotherapymayimproveprognosisofserumafpelevatedgastriccancerwithlivermetastasis AT xiaotianzhang multimodalitytreatmentincludingtripletregimenasfirstlinechemotherapymayimproveprognosisofserumafpelevatedgastriccancerwithlivermetastasis |